Gene changes in prostate cancer patients treated with enzalutamide vs. active surveillance

What is it about?

This research discusses a biomarker study conducted as part of the ENACT trial, which compared enzalutamide plus active surveillance (AS) to AS alone in patients with low- or intermediate-risk prostate cancer. The study analyzed longitudinal transcriptomic changes in patient samples over two years. Key findings include significant transcriptomic changes in patients treated with enzalutamide at Year 1, such as downregulation of androgen-receptor signaling and immune-suppressor signatures, and upregulation of immune-activated markers. Many of these changes reverted to baseline levels at Year 2 after treatment cessation. The study provides insights into molecular disease progression during AS and the effects of transient enzalutamide exposure. The observed immune modulation during treatment suggests potential for exploring immunotherapy strategies in prostate cancer.

Featured Image

Why is it important?

This research is significant because it examines the longitudinal transcriptomic changes in prostate cancer patients undergoing active surveillance (AS) with or without enzalutamide treatment. Understanding these molecular changes provides crucial insights into disease progression and treatment effects, which can inform more effective management strategies for low- and intermediate-risk prostate cancer. The study's findings on the transient nature of transcriptomic alterations, particularly in immune-related pathways, opens up new avenues for exploring immunotherapy approaches in prostate cancer treatment. Additionally, the research contributes to our understanding of how androgen receptor (AR) signaling inhibition affects tumor biology, which is essential for developing targeted therapies and optimizing treatment regimens. Key Takeaways: 1. Transcriptomic Changes: Enzalutamide treatment leads to significant transcriptomic changes in prostate cancer tumors, including downregulation of AR signaling and immune-suppressor signatures, and upregulation of immune-activated and basal-like markers. 2. Transient Effects: Many of the observed transcriptomic alterations, particularly immune-related changes, are transient and revert to baseline levels after enzalutamide treatment cessation, suggesting the potential for strategic treatment scheduling. 3. Biomarker-Guided Therapy: The study highlights the importance of expression profiling before therapy to establish a basis for biomarker-guided selection of therapeutic approaches for prostate cancer patients, potentially improving treatment outcomes and patient care.